Life Science Investing Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
Life Science Investing Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Life Science Investing Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
Life Science Investing Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer
